55 / 328
PROFILE OF AOAC EXPERT REVIEW PANEL FOR SPDS – CHONDROITIN, PDE5 INHIBITORS, & ANTHOCYANIN
METHODS
ERP Name
AOAC Expert Review Panel for Dietary Supplements –
Chondroitin, PDE5 Inhibitors, and Anthocyanin Methods
Chair(s)
Brian Schaneberg (Starbucks)
ERP Formed:
2015
Number of
Methods Adopted
1 as First Action
status
Number of Methods
Recommended
None Yet
Scope:
Review and adopt methods resulting from sole source submission of methods for dietary supplements
Roster
Chondroitin:
1.
Brian Schaneberg, Starbucks
(Chair)
2.
Jana Hildreth, Synutra Pure
3.
Martha Jennens, Covance
4.
Phillip Koerner,Phenomenex;
5.
Tom Phillips, State of MD;
6.
Curtis Phinney, Consultant;
7.
Kelly Reins, Consultant;
8.
John Spzylka, Merieux
NutriSciences; Aniko Solyom,
GAAS Corporation;
9.
Darryl Sullivan, Covance
10.
Liton Roy, Sancillo and Company;
11.
Nour Edine ES‐SAFI, Mohammad V
University Rabat
PDE5 Inhibitors:
1.
Brian Schaneberg, Starbucks
(Chair);
2.
Phil Koerner, Phenomenex;
3.
Katerina Mastovska, Covance;
4.
Tom Phillips, State of MD;
5.
Fenhong Song, FDA;
6.
John Spzylka, Mérieux
NutriSciences;
7.
Darryl Sullivan, Covance.
8.
Teresa Cain, FDA;
9.
Liton Roy, Sancilio;
10.
Jerry Zweigenbaum, Agilent.
Anthocyanins:
1.
Brian Schaneberg, Starbucks
(Chair);
2.
Phil Koerner, Phenomenex;
3.
Jungmin Lee, USDA;
4.
Melissa Phillips, NIST;
5.
Martha Jennens, Covance;
6.
Tom Phillips, State of MD;
7.
Aniko Solyom, GAAS Analytics;
8.
John Spzylka, Mérieux
NutriSciences;
9.
Darryl Sullivan, Covance
10.
Nour Eddine ES‐SAFI, Mohammed
V University;
11.
Liton Roy, Sancilio and Company;
12.
Jerry Zweigenbaum, Agilent
Technical
Documents
created/used
SMPRs for Chondroitin, PDE5 Inhibitors, and Anthocyanins
OMA Appendix K
Methods
Adopted
First Action
and Final
Action
status
AOAC 2015.11 – Chondroitin
AOAC 2015.12 ‐ PDE5 inhibitors
Final Action Methods Recommended
Additional Input
Awards/Recognitions
ERP PROFILE SUMMARIES
54